TABLE 2.
Pathogen distribution among patients with community-acquired, healthcare-associated, and hospital-acquired LRTI
| Bacteria | Community-acquired LRTI with no healthcare exposure Absolute number (%) (N = 1,395) |
Community-acquired LRTI with healthcare exposure Absolute number (%) (N = 2,212) |
LRTI diagnosed 3–7 days after admission Absolute number (%) (N = 2,760) |
|---|---|---|---|
| Streptococcus pneumoniae | 176 (12.6%) | 141 (6.4%) | 95 (3.4%) |
| Stenotrophomonas and Acinetobacter spp. | 69 (4.9%) | 161 (7.3%) | 315 (11.4%) |
| Staphylococcus aureus | 227 (16.3%) | 354 (16.0%) | 407 (14.8%) |
| Serratia, Providencia, and Proteus spp. | 66 (4.7%) | 173 (7.8%) | 225 (8.2%) |
| Pseudomonas and Burkholderia spp. | 210 (15.1%) | 539 (24.4%) | 556 (22.1%) |
| Haemophilus spp., Bordetella spp., Moraxella spp. | 276 (19.8%) | 280 (12.7%) | 302 (10.9%) |
| Citrobacter spp., Enterobacter spp, Escherichia coli, Klebsiella spp. | 371 (26.6%) | 564 (25.5%) | 860 (31.2%) |
a
LRTI, lower respiratory tract infection. Community-acquired LRTIs consist of samples taken within 0–2 days of hospital admission. Healthcare-associated LRTIs consist of samples taken within 0–2 days of hospital admission and with recent healthcare exposure. Hospital-acquired LRTIs consist of samples taken within 3–7 days of hospital admission.